Breaching the IBD efficacy ceiling, and sham surgeries

Will drugmakers finally be able to breach the efficacy ceiling in inflammatory bowel disease? And is the Food and Drug Administration being flexible enough with rare disease treatments?

We discuss all that on this week’s episode of “The Readout LOUD.”